Our previous research found that A-DLBCL showed a high frequency of the TP53 mutation, as well as concurrent abnormalities of MYC and BCL2 and/or BCL6, and most cases had a non-GCB immunophenotype. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.